X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs GSK PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA GSK PHARMA CIPLA/
GSK PHARMA
 
P/E (TTM) x 44.1 60.1 73.3% View Chart
P/BV x 3.6 11.8 30.8% View Chart
Dividend Yield % 0.4 2.1 16.9%  

Financials

 CIPLA   GSK PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
GSK PHARMA
Mar-16
CIPLA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs6223,850 16.2%   
Low Rs4582,966 15.5%   
Sales per share (Unadj.) Rs181.9332.3 54.7%  
Earnings per share (Unadj.) Rs12.944.3 29.1%  
Cash flow per share (Unadj.) Rs29.347.2 62.1%  
Dividends per share (Unadj.) Rs2.0050.00 4.0%  
Dividend yield (eoy) %0.41.5 25.2%  
Book value per share (Unadj.) Rs155.7202.7 76.8%  
Shares outstanding (eoy) m804.5184.70 949.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.010.3 29.0%   
Avg P/E ratio x42.076.9 54.5%  
P/CF ratio (eoy) x18.472.2 25.5%  
Price / Book Value ratio x3.516.8 20.6%  
Dividend payout %15.5112.9 13.8%   
Avg Mkt Cap Rs m434,516288,643 150.5%   
No. of employees `00023.04.6 499.7%   
Total wages/salary Rs m26,3384,434 594.0%   
Avg. sales/employee Rs Th6,349.16,104.5 104.0%   
Avg. wages/employee Rs Th1,143.0961.6 118.9%   
Avg. net profit/employee Rs Th449.3813.7 55.2%   
INCOME DATA
Net Sales Rs m146,30228,148 519.8%  
Other income Rs m2,2871,218 187.7%   
Total revenues Rs m148,58929,366 506.0%   
Gross profit Rs m24,7584,774 518.6%  
Depreciation Rs m13,229248 5,334.4%   
Interest Rs m1,5940-   
Profit before tax Rs m12,2225,744 212.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m026 0.0%   
Tax Rs m1,7982,018 89.1%   
Profit after tax Rs m10,3543,752 276.0%  
Gross profit margin %16.917.0 99.8%  
Effective tax rate %14.735.1 41.9%   
Net profit margin %7.113.3 53.1%  
BALANCE SHEET DATA
Current assets Rs m87,37021,462 407.1%   
Current liabilities Rs m33,08110,536 314.0%   
Net working cap to sales %37.138.8 95.6%  
Current ratio x2.62.0 129.7%  
Inventory Days Days8768 128.5%  
Debtors Days Days6216 379.5%  
Net fixed assets Rs m111,5674,717 2,365.2%   
Share capital Rs m1,609847 190.0%   
"Free" reserves Rs m123,64516,308 758.2%   
Net worth Rs m125,25417,171 729.4%   
Long term debt Rs m36,45416 227,835.0%   
Total assets Rs m209,53230,620 684.3%  
Interest coverage x8.7NM-  
Debt to equity ratio x0.30 31,234.5%  
Sales to assets ratio x0.70.9 76.0%   
Return on assets %5.712.3 46.5%  
Return on equity %8.321.9 37.8%  
Return on capital %8.533.6 25.3%  
Exports to sales %34.20 240,733.9%   
Imports to sales %8.315.1 55.4%   
Exports (fob) Rs m50,0504 1,251,242.5%   
Imports (cif) Rs m12,2034,237 288.0%   
Fx inflow Rs m51,066519 9,839.4%   
Fx outflow Rs m17,6788,320 212.5%   
Net fx Rs m33,388-7,801 -428.0%   
CASH FLOW
From Operations Rs m23,8241,386 1,719.4%  
From Investments Rs m-13,1275,010 -262.0%  
From Financial Activity Rs m-13,239-6,383 207.4%  
Net Cashflow Rs m-2,47812 -21,000.0%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 50.7 41.0%  
Indian inst/Mut Fund % 12.2 10.2 119.6%  
FIIs % 23.7 23.8 99.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 15.4 170.1%  
Shareholders   161,166 102,036 158.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 18, 2017 (Close)

TRACK CIPLA

CIPLA - UNICHEM LAB COMPARISON

COMPARE CIPLA WITH

MARKET STATS